Dyne Therapeutics (DYN) Expected to Post Quarterly Earnings on Thursday

Key Points

• Q1 2026 earnings are expected before the open on Thursday, May 14, with analysts forecasting ($0.74) EPS; Dyne reported ($0.76) last quarter and consensus projects about -$3 EPS for the current and next fiscal year.
• Shares opened at $18.84 and were trading up 7.8%, giving Dyne a market cap of $3.11 billion and a 52-week range of $8.06–$25.00.
• Insiders have sold heavily (1,552,911 shares, ~$29.7M over three months) while institutional ownership is ~96.7%; Wall Street’s consensus is a "Moderate Buy" with an average target of $35.14 amid mixed analyst ratings.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.74) per share for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 9:30 AM ET.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.02). On average, analysts expect Dyne Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Dyne Therapeutics Trading Up 7.8%

Shares of Dyne Therapeutics stock opened at $18.84 on Thursday. The firm has a 50-day simple moving average of $18.01 and a two-hundred day simple moving average of $18.58. The company has a market cap of $3.11 billion, a P/E ratio of -5.32 and a beta of 1.08. Dyne Therapeutics has a fifty-two week low of $8.06 and a fifty-two week high of $25.00. The company has a debt-to-equity ratio of 0.15, a quick ratio of 22.25 and a current ratio of 22.25.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on DYN shares. Morgan Stanley decreased their price objective on shares of Dyne Therapeutics from $50.00 to $47.00 and set an "overweight" rating for the company in a research report on Monday, March 2nd. Jefferies Financial Group reiterated a "buy" rating on shares of Dyne Therapeutics in a report on Monday, March 9th. HC Wainwright cut their price objective on shares of Dyne Therapeutics from $60.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, March 3rd. JPMorgan Chase & Co. cut their price target on shares of Dyne Therapeutics from $17.00 to $16.00 and set a "neutral" rating for the company in a report on Tuesday, January 20th. Finally, Wall Street Zen downgraded shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, May 2nd. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $35.14.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 287,956 shares of the firm's stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total value of $5,666,974.08. Following the completion of the transaction, the director owned 11,663 shares of the company's stock, valued at $229,527.84. This trade represents a 96.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,552,911 shares of company stock valued at $29,694,469. Company insiders own 14.14% of the company's stock.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. T. Rowe Price Investment Management Inc. raised its holdings in shares of Dyne Therapeutics by 523.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock valued at $343,085,000 after purchasing an additional 14,727,667 shares in the last quarter. Invesco Ltd. raised its stake in Dyne Therapeutics by 17.1% during the 4th quarter. Invesco Ltd. now owns 137,684 shares of the company's stock worth $2,693,000 after acquiring an additional 20,121 shares in the last quarter. Axxcess Wealth Management LLC acquired a new stake in Dyne Therapeutics during the 4th quarter worth $2,226,000. XTX Topco Ltd increased its stake in Dyne Therapeutics by 93.9% in the fourth quarter. XTX Topco Ltd now owns 56,661 shares of the company's stock valued at $1,108,000 after purchasing an additional 27,446 shares during the period. Finally, Virtus Investment Advisers LLC increased its stake in Dyne Therapeutics by 75.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 13,806 shares of the company's stock valued at $270,000 after purchasing an additional 5,937 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.